Epidermal Growth Factor Receptor (EGFR) and Prostaglandin-Endoperoxide Synthase 2 (PTGS2) Are Prognostic Biomarkers for Patients With Resected Colorectal Cancer Liver Metastases

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2014.354
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Epidermal Growth Factor Receptor (EGFR) in Biliary Tract Cancer

HPB
HepatologyGastroenterology
2016English

Total Tumour Volume as a Prognostic Factor in Patients With Resectable Colorectal Cancer Liver Metastases

BJS open
Surgery
2020English

Carcinoembryonic Antigen as a Prognostic Factor in Colorectal Cancer With Liver Metastases

Journal of Cancer Therapy
2015English

BRAF; Epidermal Growth Factor Receptor (EGFR)

Science-Business eXchange
2012English

Hypermethylated Epidermal Growth Factor Receptor (EGFR) Promoter Is Associated With Gastric Cancer

Scientific Reports
Multidisciplinary
2015English

Cranial Irradiation for Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Prognostic Utility of Epidermal Growth Factor Receptor (EGFR) Expression in Prostatic Acinar Adenocarcinoma

Applied Cancer Research
2019English

Estrogen Receptor Β and Epidermal Growth Factor Receptor as Early-Stage Prognostic Biomarkers of Non-Small Cell Lung Cancer

Oncology Reports
MedicineCancer ResearchOncology
2010English

AXL/epidermal Growth Factor Receptor (EGFR) Complexes in Breast Cancer - Culprits for Resistance to EGFR Inhibitors?

Breast Cancer Research
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy